Imaging Endpoints presents Poster at AACR 2014 in conjunction with Merrimack Pharmaceuticals
April 2014 – Imaging Endpoints presents Poster at AACR 2014 in conjunction with Merrimack Pharmaceuticals and Virginia C. Piper Cancer Center. The Poster, entitled “Pilot study in patients with advanced solid tumors to evaluate feasibility of ferumoxytol (FMX) as a tumor imaging agent prior to MM-398, a nanoliposomal irinotecan (nal-IRI)” presents preliminary data from a Phase 1 clinical study sponsored by Merrimack Pharmaceuticals demonstrating that ferumoxytol, an iron oxide nanoparticle, was well tolerated when used as a tumor contrast agent prior to MM-398 treatment. Imaging Endpoints was chosen by Merrimack Pharmaceuticals as their Imaging Core Lab partner for this study.
To read the full press release, click here.
